Loading clinical trials...
Loading clinical trials...
Phase 1/2 Open Label, Dose-escalation Study of the Safety and OcUlar Tolerability of a Single Intravitreal Injection of RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration (SUSHI)
Conditions
Interventions
RBM-007 Injectable Solution
Locations
4
United States
Retinal Consultants Medical Group
Sacramento, California, United States
Retinal Consultants Medical Group
Sacramento, California, United States
Stanford University
Stanford, California, United States
Bay Area Retina Associates
Walnut Creek, California, United States
Start Date
August 29, 2018
Primary Completion Date
June 26, 2019
Completion Date
June 26, 2019
Last Updated
January 5, 2021
NCT07440225
NCT05407636
NCT07308639
NCT07441642
NCT05913063
NCT07392255
Lead Sponsor
Ribomic USA Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions